H
Hans Vandekerckhove
Publications - 6
Citations - 622
Hans Vandekerckhove is an academic researcher. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 3, co-authored 3 publications receiving 306 citations.
Papers
More filters
Journal ArticleDOI
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
John R. Teerlink,Rafael Diaz,G. Michael Felker,John J.V. McMurray,Marco Metra,Scott D. Solomon,Kirkwood F. Adams,Inder S. Anand,Alexandra Arias-Mendoza,Tor Biering-Sørensen,Michael Böhm,Diana Bonderman,John G.F. Cleland,John G.F. Cleland,Ramón Corbalán,María G. Crespo-Leiro,Ulf Dahlström,Luis E. Echeverría,James C. Fang,Gerasimos Filippatos,Cândida Fonseca,Eva Goncalvesova,Assen Goudev,Jonathan G. Howlett,David E. Lanfear,Jing Li,M. Lund,Peter S. Macdonald,Viacheslav Mareev,Shin-ichi Momomura,Eileen O'Meara,Alexander Parkhomenko,Piotr Ponikowski,Felix José Alvarez Ramires,Pranas Šerpytis,Karen Sliwa,Jindrich Spinar,Thomas M. Suter,János Tomcsányi,Hans Vandekerckhove,Dragos Vinereanu,Adriaan A. Voors,Mehmet Yilmaz,Faiez Zannad,Lucie Sharpsten,Jason C. Legg,Claire Varin,Narimon Honarpour,Siddique Abbasi,Fady I. Malik,Christopher E. Kurtz +50 more
TL;DR: Among patients with heart failure and a reduced ejection, patients who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo.
Journal ArticleDOI
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
John R. Teerlink,John R. Teerlink,G. Michael Felker,John J.V. McMurray,Scott D. Solomon,Kirkwood F. Adams,John G.F. Cleland,John G.F. Cleland,Justin A. Ezekowitz,Assen Goudev,Peter S. Macdonald,Marco Metra,Veselin Mitrovic,Piotr Ponikowski,Pranas Šerpytis,Jindrich Spinar,János Tomcsányi,Hans Vandekerckhove,Adriaan A. Voors,Maria Laura Monsalvo,James A. Johnston,Fady I. Malik,Narimon Honarpour +22 more
TL;DR: Omecamtiv mecarbil dosing guided by pharmacokinetics achieved plasma concentrations associated with improved cardiac function and decreased ventricular diameter, and the frequency of adverse clinical events did not differ between groups.
Journal ArticleDOI
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.
John R. Teerlink,Rafael Diaz,G. Michael Felker,John J.V. McMurray,Marco Metra,Scott D. Solomon,Kirkwood F. Adams,Inder S. Anand,Alexandra Arias-Mendoza,Tor Biering-Sørensen,Michael Böhm,Diana Bonderman,John G.F. Cleland,John G.F. Cleland,Ramón Corbalán,María G. Crespo-Leiro,Ulf Dahlström,Luis E. Echeverría Correa,James C. Fang,Gerasimos Filippatos,Cândida Fonseca,Eva Goncalvesova,Assen Goudev,Jonathan G. Howlett,David E Lanfear,M. Lund,Peter S. Macdonald,Vyacheslav Mareev,Shin-ichi Momomura,Eileen O'Meara,Alexander Parkhomenko,Piotr Ponikowski,Felix J. A. Ramires,Pranas Šerpytis,Karen Sliwa,Jindrich Spinar,Thomas M. Suter,János Tomcsányi,Hans Vandekerckhove,Dragos Vinereanu,Adriaan A. Voors,Mehmet Yilmaz,Faiez Zannad,Lucie Sharpsten,Jason C. Legg,Siddique Abbasi,Claire Varin,Fady I. Malik,Christopher E. Kurtz,Galactic-Hf Investigators +49 more
TL;DR: The baseline characteristics of participants in GALACTIC‐HF are described and how these compare with other contemporary trials are described.
Journal ArticleDOI
Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics
Wilfried Mullens,Jeroen Dauw,Pieter Martens,E. Meekers,Petra Nijst,Frederik H. Verbrugge,Fabien Chenot,Samer Al Moubayed,Riet Dierckx,Philippe Blouard,David Derthoo,Walter Smolders,Bavo Ector,Michael Hulselmans,Stijn Lochy,David F.J. Raes,Emeline M. Van Craenenbroeck,Hans Vandekerckhove,Pieter-Jan Hofkens,Kathleen Goossens,Anne-Catherine Pouleur,Michel de Ceuninck,Laurence Gabriel,P. Timmermans,Edgard A. Prihadi,Frederik Van Durme,Michel Depauw,Delphine Mtf Vervloet,Els Viaene,Jean-Luc Vachiery,Katrien Tartaglia,Jozine M. ter Maaten,Liesbeth Bruckers,Walter Droogne,Pierre Troisfontaines,Kevin Damman,Johan Lassus,Alexandre Mebazaa,Gerasimos Filippatos,Frank Ruschitzka,Matthias Dupont +40 more
TL;DR: The baseline characteristics of participants in the Acetazolamide in Decompensated Heart Failure with Volume Overload (ADVOR) trial are described and these are compared with other contemporary diuretic trials in acute heart failure.
Journal ArticleDOI
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B‐type natriuretic peptide level: insights from the GALACTIC‐HF trial
Kieran F. Docherty,John J.V. McMurray,Brian Claggett,Zi Michael Miao,Kirkwood F. Adams,Alexandra Arias-Mendoza,John G.F. Cleland,Rafael Diaz,Luis E. Echeverría Correa,G. Michael Felker,Candida Fonseca,Jing Li,Marco Metra,Karen Sliwa-Hahnle,Scott D. Solomon,Hans Vandekerckhove,Dragos Vinereanu,Adriaan A. Voors,Stephen B. Heitner,Stuart Kupfer,Fady I. Malik,Lisa Meng,John R. Teerlink +22 more
TL;DR: In this article , the authors examined the effect of the cardiac myosin activator omecamtiv mecarbil according to baseline NT-proBNP level in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure trial (GALACTIC‐HF).